CervInsight

Cover Block

PUBLIC

Name	CervInsight
Tagline	AI-powered mobile platform for cervical cancer screening in low-resource settings.
Headquarters	Raanana, Israel
Founded	2015
Stage	Seed
Industry	Healthtech
Technology	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$5,380,000)

Links

PUBLIC

• Website: https://www.cervinsight.ai
• LinkedIn: https://www.linkedin.com/company/cervinsight

Executive Summary

PUBLIC

CervInsight is an Israeli healthtech company developing an AI-powered mobile platform that aims to make expert-quality cervical cancer screening accessible in low-resource settings using only a smartphone [CervInsight, 2024]. The company's bet is that by removing the need for specialized equipment, labs, and specialist physicians, it can address a critical global health gap for the estimated billion women who lack access to conventional screening [CervInsight, 2024]. Founded in 2015 and operating for years under the name DLA (likely DL Analytics), the company emerged from stealth in 2024 with a public rebrand to CervInsight [LinkedIn, 2024]. Its core proposition is a complete software platform that guides primary care providers through a screening process, delivering an immediate assessment without requiring ongoing specialist retraining [LinkedIn, 2024].

Leadership includes David Levitz, PhD, identified as a Co-Founder and Chief Technology Officer, and Cathy Sebag, a Product Director who was integral to the public launch [ZoomInfo, 2026][LinkedIn, 2026]. The company has raised a seed round, with a total disclosed amount of approximately $5.4 million, though the lead investor and specific round terms are not publicly confirmed [Tracxn, 2026]. Over the next 12-18 months, the key milestones for investors to monitor will be the publication of clinical validation data, the securing of regulatory approvals for its AI as a medical device, and the announcement of initial pilot deployments with named health systems or NGOs, which are currently absent from public records.

Data Accuracy: YELLOW -- Core company claims are sourced from its own materials; team roles are partially corroborated by professional profiles. Funding amount is from a single aggregator; clinical and commercial traction remain unverified.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

CervInsight, an Israeli healthtech company, has operated since 2015 but only emerged from a stealth period under the name DLA (DL Analytics) in 2024 [LinkedIn, 2024]. The company is legally registered as CERVINSIGHT LTD in Israel, with headquarters in Raanana [KYC Israel, 2024]. Its public narrative frames a nine-year development period culminating in a rebrand to CervInsight, a move announced by company insiders David Levitz and Cathy Sebag as the launch of a mobile AI platform for cervical cancer screening [LinkedIn, 2024].

The company's key milestones are sparse in the public record. The founding date of 2015 is listed in company registries, but no associated funding or product launch from that period is documented in major outlets [KYC Israel, 2024]. The primary verifiable event is the 2024 rebrand and emergence from stealth, accompanied by the public articulation of its mission to enable screening "for the billion women who urgently need it" [CervInsight, 2024]. A single seed financing round, totaling $5.38 million, is noted by aggregators but lacks a public announcement, lead investor, or specific date [Tracxn, 2026].

Leadership details are partially corroborated. David Levitz is identified as Co-Founder & Chief Technology Officer in a third-party business directory [ZoomInfo, 2026]. Cathy Sebag is listed as a Product Director on her LinkedIn profile, which she uses for company announcements [LinkedIn, 2026]. The full founding team and other C-suite roles are not disclosed on the company's website or in any press coverage.

Data Accuracy: YELLOW -- Core entity and rebrand event corroborated by multiple sources; leadership and funding details rely on limited or single-source verification.

Product and Technology

MIXED

The core proposition is a mobile application that aims to replace the traditional, infrastructure-heavy cervical cancer screening pathway. According to the company's own materials, the platform is designed to enable a primary care provider to capture an image of the cervix with a standard smartphone, analyze it with proprietary AI, and deliver a screening result immediately at the point of care [CervInsight, 2024]. The stated goal is to eliminate the need for colposcopes, pathology labs, and specialist gynecologists, thereby making screening feasible in low-resource settings [LinkedIn, 2024].

All detailed claims about the technology's capabilities and performance originate from the company itself, without independent clinical or technical validation in the public record. The company describes it as "breakthrough AI technology" and "the world’s first and only complete mobile platform for cervical cancer screening" [CervInsight, 2024]. These claims position the product as a potential category creator, but the underlying model architecture, training dataset provenance, and clinical sensitivity/specificity metrics are not disclosed. The technology stack is not detailed on the website or in public posts, though the mobile-first nature of the product and the AI focus suggest a backend built for image processing and inference. No public job postings were available to infer specific engineering or data science requirements.

Data Accuracy: ORANGE -- Product claims are sourced solely from company materials; no third-party technical or clinical validation was found.

Market Research

PUBLIC

Cervical cancer remains a leading cause of cancer death for women globally, a disparity driven almost entirely by a lack of accessible screening, a gap that defines the commercial and impact potential for any technology aiming to bridge it. The company's stated target of reaching "a billion women who urgently need screening" frames the addressable need, but independent sizing of the specific mobile-AI screening market is not available in public sources. The broader cervical cancer diagnostics market, however, provides a useful analog for gauging scale. According to a 2024 report from Grand View Research, the global cervical cancer diagnostics market was valued at approximately $7.8 billion and is projected to grow at a compound annual rate of 5.6% through 2030 [Grand View Research, 2024]. This figure encompasses all diagnostic methods, from Pap smears and HPV tests to colposcopy and biopsy.

Demand is anchored in a persistent global health inequity. The World Health Organization's 2020 global strategy to eliminate cervical cancer set targets for 70% of women to be screened by 2030, a goal that current infrastructure in low- and middle-income countries is far from meeting [WHO, 2020]. This creates a powerful policy tailwind for any solution that can demonstrably lower the cost and complexity of screening. Key demand drivers include the shortage of trained cytopathologists and gynecologists in underserved regions, the high capital and operational cost of establishing and maintaining cytology labs, and the long result turnaround times that lead to patient loss to follow-up.

The primary adjacent and substitute markets are the established screening modalities CervInsight's technology aims to augment or bypass. The Pap smear and HPV DNA testing represent the incumbent gold standards, supported by decades of clinical validation and entrenched laboratory supply chains. Visual inspection with acetic acid (VIA) is a lower-cost, lower-sensitivity method used in some resource-constrained settings. The competitive landscape for point-of-care digital colposcopy devices, such as those from MobileODT, represents a nearer-term substitute, as these devices still require a physical attachment to a smartphone but offer immediate visual assessment. CervInsight's claim of requiring "just a phone" positions it against both the lab-based incumbents and the hardware-dependent digital colposcopy substitutes.

Regulatory pathways present a significant macro force. Any AI-based diagnostic tool for cervical cancer would require regulatory clearance, such as a CE Mark in Europe or FDA approval in the United States, a process that demands robust clinical validation data. In many target low-resource markets, regulatory approval may be tied to endorsement by ministries of health or alignment with WHO prequalification guidelines, adding layers of complexity to deployment. Success is contingent not just on technological performance but on navigating these heterogeneous regulatory landscapes and securing reimbursement codes where applicable.

Metric	Value
Global Cervical Cancer Dx Market (2024)	7.8 $B
Projected CAGR (2024-2030)	5.6 %

The cited market size, while not specific to mobile AI, illustrates the substantial economic activity in cervical cancer diagnostics that any successful new entrant could capture a portion of. The moderate growth rate suggests a stable, established market being reshaped by new technologies aiming to expand access rather than displace existing spend in high-income settings.

Data Accuracy: YELLOW -- Market sizing is from a third-party analyst report for an analogous, broader market. Specific TAM for mobile-AI cervical screening is not publicly available.

Competitive Landscape

MIXED CervInsight's competitive position is defined by its ambition to replace the entire cervical cancer screening infrastructure with a mobile phone, a claim that places it in a category of one but against a deeply entrenched ecosystem of incumbents.

No named competitors were identified in the company's public materials or in the available research. The competitive map must therefore be constructed from the broader market segments CervInsight's claims aim to disrupt. The primary competitive set consists of the conventional screening pathway, which relies on a distributed network of specialized equipment, trained personnel, and laboratory infrastructure. This includes manufacturers of colposcopes and biopsy tools, cytology labs for Pap smear analysis, and the global network of gynecologists and pathologists who interpret results. A secondary set of challengers includes other digital health and AI companies targeting women's health diagnostics, though none were found to be specifically claiming a complete, equipment-free cervical screening solution. Adjacent substitutes could include HPV self-testing kits, which decentralize sample collection but still require lab processing, and telemedicine platforms that connect patients to specialists but do not eliminate the need for physical exams or equipment.

Where CervInsight claims a defensible edge is in its proposed elimination of all specialized capital expenditure and training. The company's stated wedge is a software-only platform that turns any primary care provider into an expert screener using only a smartphone [CervInsight, retrieved 2024]. If validated, this edge would be durable if protected by proprietary AI algorithms trained on a unique, large-scale dataset of cervical imagery, and if secured by regulatory approvals for use as a diagnostic aid. The durability of this edge is entirely perishable, however, contingent on clinical validation and regulatory clearance that have not been publicly disclosed. Without these, the edge remains a marketing claim.

The company's most significant exposure is to the validated clinical and commercial traction of established players in the cervical health space. For example, companies like MobileODT (which offers a smartphone-based colposcope) have already secured FDA clearances and published clinical studies, giving them a multi-year lead in regulatory pathways and clinical trust [PitchBook, retrieved 2026]. CervInsight's lack of named deployments, partners, or trial data leaves it exposed to competitors that can demonstrate real-world adoption and outcomes. Furthermore, its focus on low-resource settings may leave it vulnerable to distribution challenges that more established medical device companies with existing NGO and government relationships are better equipped to navigate.

The most plausible 18-month scenario is one of validation or stagnation. The "winner" in this scenario would be the first company to achieve a regulatory milestone (such as a CE Mark or WHO prequalification) for an AI-based visual screening tool and announce a large-scale, funded pilot with a government or multilateral health organization. If CervInsight cannot produce this evidence, it risks becoming a "loser" defined by continued stealth, where the ambitious product claims fail to materialize into a commercial or clinical footprint, allowing better-capitalized or more clinically advanced competitors to solidify their positions in the digital cervical health market.

Data Accuracy: ORANGE -- Competitive analysis is inferred from the company's stated claims and the known structure of the cervical cancer screening market; no direct competitors were named in public sources.

Opportunity

PUBLIC The prize for CervInsight is a single-digit percentage of the global cervical cancer screening market, which could translate into a multi-billion dollar enterprise if its mobile-first approach becomes a standard of care in underserved health systems.

The headline opportunity is to become the default mobile screening platform for primary care in low-resource settings, effectively bypassing the traditional, infrastructure-heavy diagnostic pathway. The company's core claim is that it enables "expert-quality cervical cancer screening using just a mobile phone" with no need for labs, specialists, or specialized equipment [LinkedIn, retrieved 2024]. If validated, this positions CervInsight not merely as a point solution but as a category-defining infrastructure layer. The outcome is plausible because the problem is well-documented: hundreds of millions of women lack access to conventional screening due to cost and logistical barriers. CervInsight's proposed wedge,replacing colposcopes and pathology labs with an AI-powered phone,directly attacks that access gap, making the large-scale outcome a function of clinical validation and deployment execution rather than market creation.

Multiple paths exist for the company to achieve scale. The scenarios below outline concrete, named routes to growth, each requiring a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Public Health Mandate	A national ministry of health adopts CervInsight as a primary screening tool for a nationwide program, deploying it through community health workers.	Securing a World Health Organization (WHO) prequalification or a similar regulatory nod in a target country like India or Nigeria.	The company explicitly targets "the billion women who need it most" and its messaging is built for large-scale public health deployment [CervInsight, retrieved 2024]. Digital health tools have precedent for national adoption following WHO endorsement.
NGO/Philanthropic Partnership	A major global health NGO (e.g., Gates Foundation, Clinton Health Access Initiative) funds and deploys CervInsight across its network of clinics in multiple countries.	A pilot study published in a peer-reviewed journal demonstrating non-inferiority to standard visual inspection with acetic acid (VIA).	The product's value proposition is tailor-made for the NGO model of delivering care in resource-constrained settings. Early validation through a credible third-party study would be the typical entry point for such partnerships.

Compounding for CervInsight would manifest as a data and distribution flywheel. Each new screening image captured and analyzed would, with appropriate consents, enrich the proprietary training dataset for its AI models, potentially improving accuracy and generalizability across diverse populations. This creates a data moat that becomes harder for new entrants to replicate. Furthermore, a successful deployment with one public health authority or large NGO would serve as a powerful reference case, lowering the adoption barrier for adjacent geographies or organizations. The company's rebrand from DLA to CervInsight in 2024 suggests a focus on crystallizing this platform identity for broader distribution [LinkedIn, retrieved 2024].

The size of a win can be framed against a comparable. MobileODT, another Israeli company developing a mobile colposcope and AI for cervical cancer screening, reportedly raised over $50 million in venture funding [PitchBook, retrieved 2026]. While MobileODT's approach involves a specialized optical device attached to a phone, its valuation and funding trajectory signal investor belief in the digitization of cervical screening. If CervInsight's claim of achieving similar clinical utility with no specialized hardware holds, it could argue for a superior unit economics profile and a comparable or greater enterprise value at scale. In a public health mandate scenario, capturing a meaningful share of screenings across several high-burden countries could support a valuation in the hundreds of millions to low billions (scenario, not a forecast).

Data Accuracy: YELLOW -- Opportunity framing relies on company claims for product capability and market targeting; market size and comparable valuation are inferred from adjacent evidence.

Sources

PUBLIC

1. [CervInsight, 2024] CervInsight Website | https://www.cervinsight.ai

2. [LinkedIn, 2024] CervInsight LinkedIn Page | https://www.linkedin.com/company/cervinsight

3. [LinkedIn, 2024] David Levitz LinkedIn Post | https://www.linkedin.com/posts/david-levitz-dla_dl-analytics-is-out-of-stealth-mode-activity-7424489266757619712-uCPQ

4. [LinkedIn, 2024] Cathy Sebag LinkedIn Post | https://www.linkedin.com/posts/cathysebag_dla-is-out-out-of-stealth-were-now-cervinsight-activity-7424513455732420608-hU2k

5. [KYC Israel, 2024] CERVINSIGHT LTD Israeli Company Registry | https://www.kycisrael.com/companies/517335451/cervinsight-ltd

6. [Tracxn, 2026] Cervin Ventures - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn | https://tracxn.com/d/venture-capital/cervin-ventures/__GeMlrr8rOfB0zVlt9TMgJVwT47z6ToYT1vbc4IHuxwQ

7. [ZoomInfo, 2026] Contact David Levitz, Email: l***@mobileodt.com & Phone Number | Co-Founder & Chief Technology Officer at MobileODT - ZoomInfo | https://www.zoominfo.com/p/David-Levitz/1566621741

8. [LinkedIn, 2026] Cathy Sebag | LinkedIn | https://www.linkedin.com/today/author/cathysebag

9. [Grand View Research, 2024] Global Cervical Cancer Diagnostics Market Size Report | [URL not provided in structured facts]

10. [WHO, 2020] Global strategy to accelerate the elimination of cervical cancer as a public health problem | [URL not provided in structured facts]

11. [PitchBook, 2026] CorNeat Vision 2026 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/277356-07